Novartis’ Failed Cholesterol Drug Trial Sends Ionis and Amgen Tumbling

insidermonkey.com · 2026-09-13

Few concepts in cardiovascular medicine have sparked as much optimism as Lp(a)-lowering medications.

TickrTrends take: The failure of Novartis' cholesterol drug trial creates uncertainty around the broader class of therapies that both Ionis and Amgen are developing, potentially impacting revenue projections for pipeline assets in this category. Given that TickrTrends currently rates AMGN as overvalued, investors focused on valuation metrics should monitor whether the market reprices the company's cholesterol drug candidates and what effect this has on near-term earnings estimates. The negative trial results may provide a testing point for whether AMGN's current valuation already reflects meaningful risks to its cardiovascular drug portfolio.

Read the full story at insidermonkey.com →